You are here

FDA Approves Pazeo (Olopatadine) Solution for Ocular Allergy Itch Relief

Product launch expected in March

The FDA has approved Pazeo (olopatadine hydrochloride ophthalmic solution 0.7%, Alcon) for the treatment of ocular itching associated with allergic conjunctivitis. The solution is dosed one drop daily and was approved with efficacy data at 24 hours post-dose.

Up to 30% of the U.S. population is affected by seasonal allergy symptoms, and up to 70% to 80% of these individuals experience ocular symptoms, such as itchy eyes.

Results from two clinical studies showed that olopatadine hydrochloride ophthalmic solution 0.7%, provided significantly improved relief of ocular itching associated with allergic conjunctivitis at 24 hours post-treatment compared with olopatadine 0.2% (Pataday solution, Alcon). The safety profile of the olopatadine 0.7% solution was comparable with that of olopatadine 0.2%. In the two studies, the most common adverse events included blurred vision, dry eye, superficial punctate keratitis, dysgeusia, and abnormal sensations in the eye.

Pazeo solution 0.7% is expected to be available by prescription in the U.S. in March 2015.

Allergic conjunctivitis is not typically harmful to a person’s eyes or vision; however, it can cause discomfort. The most common subtypes of allergic conjunctivitis are seasonal allergic conjunctivitis, which lasts for a short period, and perennial allergic conjunctivitis, a chronic, year-round condition.

Source: Alcon; February 2, 2015.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function